Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?

BMC Pulmonary Medicine

Hans Klose²  Tim H Brümmendorf²  Carsten Bokemeyer²  Stefan Kluge¹  Friedemann Honecker²  Hans Jörg Baumann²  Gunhild Keller²  Jan K Hennigs¹ 

[1] Department of Critical Care Medicine, University Medical Centre Hamburg - Eppendorf, 20246 Hamburg, Germany;Department of Internal Medicine II - Oncology, Haematology, BMT and Pneumology, University Medical Centre Hamburg - Eppendorf, 20246 Hamburg, Germany

关键词: side effects;    leukaemia;    antiproliferative therapy;    drug induced;    Pulmonary hypertension;   

Others  :  1172547
DOI  :  10.1186/1471-2466-11-30

 received in 2010-11-02, accepted in 2011-05-23,  发布年份 2011

【 摘 要 】

Background

Pulmonary hypertension (PH) is a life-threatening disease with poor prognosis. Encouraging efforts have been made to target the main vasoproliferative aspects of the disease. Promising emerging therapeutics are tyrosine kinase inhibitors such as imatinib.

Case presentation

Here, we discuss the relevance of previously published cases and add another well-characterised patient who developed pre-capillary PH under long-term therapy with the multi-tyrosine kinase inhibitor dasatinib approved for therapy of chronic myeloic leukaemia (CML) and Philadelphia chromosome positive acute lymphocytic leukaemia (mean time of all patients on dasatinib: 26 months). Hence, we discuss the possibility of dasatinib itself causing PH after long-term therapy and turn specialist's attention to this possible severe side effect.

At present, the true incidence of dasatinib-associated PH remains illusive and systematic data regarding haemodynamics are missing.

Conclusion

We therefore recommend systematic screening of dasatinib-treated patients for pulmonary hypertension and subsequent collection of haemodynamic data.

【 授权许可】

   
2011 Hennigs et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Humbert M, Sitbon O, Simonneau G: Treatment of pulmonary arterial hypertension. N Engl J Med 2004, 351(14):1425-1436.
• [2]Michelakis ED, Weir EK: Anorectic drugs and pulmonary hypertension from the bedside to the bench. Am J Med Sci 2001, 321(4):292-299.
• [3]EMEA: Sprycel - Scientific Discussion. European Public Assessment Report (EPAR) 2008. (EMEA/H/C/709)
• [4]FDA: Dasatinib - Pharmacogenomic Information: Indications and Usage. 2010.
• [5]Rasheed W, Flaim B, Seymour JF: Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res 2009, 33(6):861-864.
• [6]Mattei D, Feola M, Orzan F, Mordini N, Rapezzi D, Gallamini A: Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant 2009, 43(12):967-968.
• [7]Bergeron A, Rea D, Levy V, Picard C, Meignin V, Tamburini J, Bruzzoni-Giovanelli H, Calvo F, Tazi A, Rousselot P: Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med 2007, 176(8):814-818.
• [8]Quintás-Cardama A, Kantarjian H, O'brien S, Borthakur G, Bruzzi J, Munden R, Cortes J: Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007, 25(25):3908-3914.
• [9]Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, et al.: Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009, 34(6):1219-1263.
• [10]Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, et al.: Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009, 54(1 Suppl):S43-54.
• [11]Guilpain P, Montani D, Damaj G, Achouh L, Lefrère F, Le Pavec J, Marfaing-Koka A, Dartevelle P, Simonneau G, Humbert M, et al.: Pulmonary hypertension associated with myeloproliferative disorders: a retrospective study of ten cases. Respiration 2008, 76(3):295-302.
• [12]Harch S, Whitford H, McLean C: Failure of medical therapy in pulmonary arterial hypertension. Is there an alternative diagnosis? Chest 2009, 135(6):1462-1469.
• [13]Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, et al.: Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005, 115(10):2811-2821.
• [14]Ghofrani HA, Seeger W, Grimminger F: Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005, 353(13):1412-1413.
• [15]Patterson KC, Weissmann A, Ahmadi T, Farber HW: Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med 2006, 145(2):152-153.
• [16]Souza R, Sitbon O, Parent F, Simonneau G, Humbert M: Long term imatinib treatment in pulmonary arterial hypertension. Thorax 2006, 61(8):736.
• [17]Grinnan DC, Fairman P, Pinson J: Recurrence of severe pulmonary hypertension following the removal of a lung allograft. Chest 2007, 132(6):2057-2058. author reply 2058
• [18]Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, Barst RJ, Shapiro S, Golpon H, Toshner M, Grimminger F, et al.: Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010, 182(9):1171-1177.
• [19]Rix U, Hantschel O, Dürnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, Kaupe I, Bennett KL, Valent P, Colinge J, et al.: Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007, 110(12):4055-4063.